Share chart Biogen
Extended chart
Simple chart
About Biogen
Biogen Inc. — американская многонациональная биотехнологическая компания, базирующаяся в Кембридже, штат Массачусетс, специализирующаяся на открытии, разработке и поставке методов лечения нейродегенеративных, гематологических и аутоиммунных заболеваний пациентам во всем мире.
Main settings
IPO date
1991-09-16
ISIN
US09062X1037
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Дивиденд ао
22.23
Сайт
Grade
Underestimation
Title | Value | Grade |
P/S | 2.26 | 6 |
P/BV | 1.31 | 9 |
P/E | 13.43 | 8 |
Efficiency
Title | Value | Grade |
ROA | 5.95 | 2 |
ROE | 10.36 | 4 |
ROIC | 8.77 | 3 |
Dividends
Title | Value | Grade |
Dividend yield | 0 | 0 |
DSI | 0.5 | 5 |
Average dividend growth | 0 | 0 |
Debt
Title | Value | Grade |
Debt/EBITDA | 2.55 | 5 |
Debt/Ratio | 0.2364 | 10 |
Debt/Equity | 0.678 | 9 |
Growth impulse
Title | Value | Grade |
Yield Revenue, % | -28.01 | 0 |
Yield Ebitda, % | -68.39 | 0 |
Yield EPS, % | -54.89 | 0 |
Prices
Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
Yesterday | 133.11 $ | 0 $ | 0 $ | -4.21 % | 0 % | 0 % |
Week | 134.46 $ | 127.5 $ | 133.11 $ | -5.18 % | 0 % | 0 % |
Month | 133.06 $ | 124.76 $ | 135.33 $ | -4.18 % | 0 % | 0 % |
Three month | 120.17 $ | 116.49 $ | 135.49 $ | +6.1 % | 0 % | 0 % |
Half a year | 141.27 $ | 113.38 $ | 150.71 $ | -9.75 % | 0 % | 0 % |
Year | 195.81 $ | 113.38 $ | 227.44 $ | -34.89 % | 0 % | 0 % |
3 years | 266.67 $ | 113.38 $ | 324.5 $ | -52.19 % | 0 % | 0 % |
5 years | 279.75 $ | 113.38 $ | 422.32 $ | -54.42 % | 0 % | 0 % |
10 years | 287.38 $ | 113.38 $ | 422.32 $ | -55.63 % | 0 % | 0 % |
Year to date | 139.39 $ | 113.38 $ | 153.27 $ | -8.53 % | 0 % | 0 % |
Insider trading
Main owners
Contained in ETF
ETF | Share, % | Profitability for 1 year, % | Commission, % |
PSYK ETF | 4.07 | 0 | 0.75 |
Future Tech ETF | 2.81727 | 479.5 | 0.35 |
Principal Healthcare Innovators ETF | 2.81727 | -3.92 | 0.35 |
IQ U.S. Mid Cap R&D Leaders ETF | 2.48 | 0 | 0.16 |
John Hancock Multifactor Healthcare ETF | 2.34 | 29.34 | 0.40 |
iShares Evolved U.S. Innovative Healthcare ETF | 2.29 | 0.000586 | 0.18 |
Invesco S&P 500® Equal Weight Health Care ETF | 1.77 | 815.08 | 0.40 |
Nationwide Maximum Diversification U.S. Core Equity ETF | 1.52 | 26.65 | 0.34 |
IQ Engender Equality ETF | 1.05205 | 3.37 | 0.45 |
Knowledge Leaders Developed World ETF | 0.91244 | -5.59 | 0.75 |
JPMorgan Corporate Bond Research Enhanced ETF | 0.32 | -0.2672 | 0.09 |
iShares Morningstar Mid-Cap ETF | 0.26833 | 245.03 | 0.04 |
Nationwide Nasdaq-100 Risk-Managed Income ETF | 0.19851 | 7.59 | 0.68 |
JPMorgan U.S. Aggregate Bond ETF | 0.18 | 0.5961 | 0.07 |
iShares Morningstar Large-Cap Value ETF | 0.11151 | 51.43 | 0.25 |
Columbia U.S. ESG Equity Income ETF | 0.10133 | -4.51 | 0.35 |
iShares Morningstar Large-Cap ETF | 0.05802 | 186.3 | 0.03 |
1.37 | 107.68 | 0.33 |
---|
Similar companies
P/E & P/BV
Company management
Head | Job title | Payment | Year of birth |
Ms. Robin C. Kramer | Senior VP & Chief Accounting Officer | N/A | 1966 (59 years) |
Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | N/A | |
Ms. Nicole Murphy | Head of Pharmaceutical Operations & Technology | 1.46M | 1973 (52 years) |
Mr. Michael R. McDonnell CPA | Executive VP & CFO | 2.12M | 1964 (61 year) |
Ms. Susan H. Alexander Esq. | Executive VP & Chief Legal Officer | 2.2M | 1957 (68 years) |
Mr. Christopher A. Viehbacher | President, CEO & Director | 487.94k | 1961 (64 years) |
Mr. Charles E. Triano | Senior VP & Head of Investor Relations | N/A | |
Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | N/A | 1977 (48 years) |
Mr. Rachid Izzar | Head of Global Product Strategy & Commercialization | 1975 (50 years) | |
Dr. Ginger Gregory Ph.D. | Executive VP & Chief Human Resources Officer | 1968 (57 years) |
About company
Address: United States, Cambridge, 225 Binney Street - Open in google maps, Open in yandex maps
Website: http://www.biogen.com
Website: http://www.biogen.com